论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors He L, Zhang S, Zhang X, Liu R, Guan H, Zhang H
Received 2 September 2017
Accepted for publication 1 November 2017
Published 24 November 2017 Volume 2017:10 Pages 5621—5631
DOI https://doi.org/10.2147/OTT.S150701
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Purpose: This study was aimed to investigate the expressions of the insulin
receptor (IR), insulin-like growth factor receptor (IGF-1R), and glucagon-like
peptide-1 receptor (GLP-1R) in normal thyroid tissue, papillary thyroid cancer
(PTC) tissues, and PTC cells, and to examine the possible role of insulin
analogs and GLP-1R agonists in cell proliferation and energy metabolism in PTC
cells.
Methods: The expressions of IR, IGF-1R, and GLP-1R in PTC tissues and PTC
cell lines were detected by immunohistochemistry and western blotting,
respectively. Cell proliferation was evaluated by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Levels of
members of the phosphoinositol-3 kinase/AKT serine/threonine kinase (Akt) and
mitogen-activated protein kinase/extracellular signal-regulated kinase (Erk)
signaling pathways were measured by western blotting. Energy metabolism of PTC
cell lines was analyzed using a Seahorse Extracellular Flux analyzer.
Results: Three receptors could be detected in both PTC tissues and PTC cell
lines. Expressions of IGF-1R and GLP-1R were more obvious in PTC than in normal
thyroid cells. Neither insulin, four insulin analogs, and two GLP-1R agonists
showed significant effects on the proliferation of PTC cells, nor did they influence
the levels of Akt/p-Akt and Erk/p-Erk. None of these antidiabetic agents could
change the mitochondrial respiration and glycolysis levels in PTC cell lines.
Conclusion: Both PTC tissues and the PTC cell lines express IR, IGF-1R, and
GLP-1R. However, insulin analogs and GLP-1R agonists, which are commonly used
to treat patients with diabetes, may not influence cell proliferation, the
phosphoinositol-3 kinase/Akt and mitogen-activated protein kinase/Erk pathways,
or energy metabolism in PTC cells. For now, it is not necessary to avoid use of
these antidiabetic agents in patients with PTC.
Keywords: insulin analog, GLP-1R agonist, diabetes mellitus, papillary thyroid
cancer